AtuFECT01
AtuFECT01 is a cationic lipid component. AtuFECT01 is used to construct AtuPLEX/Atu027 Lipid nanoparticles. AtuFECT01 improves cellular uptake and endosomal escape of siRNA in AtuFECT01-based lipoplexes. Formulation of AtuFECT01 with Tie2 siRNA into lipoplexes reduces Tie2 expression in mouse lung.
Para uso exclusivo en investigación. No vendemos a pacientes.
- No. CAS: 869094-19-9
- Fòrmula: C43H90Cl3N7O2
- Peso molecular:843.58
-
Almacenamiento:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
DACC/AtuFECT01 lipoplexes (0.75-3 mg siRNA/kg; intravenous bolus; single or once daily; 3 consecutive days) mediate dose-dependent, lung endothelial-specific knockdown of Tie-2, CD31, VEGFR2, VE-Cadherin, and BMPR-2 in C57Bl/6j healthy mice[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Hsd:NMRI-nu/nu nude (male, 9 weeks)[2]
-
Dosage:1.88 mg/kg siRNA and 14.5 mg/kg lipid
-
Administration:i.v. via tail vein; once daily; four consecutive days
-
Result:Reduced Tie2 mRNA in lung, heart, and liver after siRNA^Tie2-lipoplex administration.
Reduced CD31 mRNA in lung, heart, and liver after siRNA^CD31-lipoplex administration.
Reduced Tie2 mRNA more prominently than CD31 mRNA in liver.
Inhibited both target genes similarly in lung and heart.
Reduced Tie2 protein in all three analyzed organs after siRNA^Tie2-lipoplex administration.
Reduced CD31 protein in lung and heart after siRNA^CD31-lipoplex administration.
Reduced serum soluble Tie2 on day 5 in siRNA^Tie2-lipoplex-administered mice compared with sucrose, siRNA^PTEN, and siRNA^CD31 control cohorts.
Observed no suppression of endothelial gene expression in kidney and spleen.
Chemical Information
-
No. CAS 869094-19-9
-
Peso molecular 843.58
-
Fòrmula C43H90Cl3N7O2
-
SMILES
N=C(N)NCCC[C@H](N)C(NC[C@H](N)C(N(CCCCCCCCCCCCCCCC)CCCCCCCC/C=C\CCCCCCCC)=O)=O.Cl.Cl.Cl
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureza y Documentación
Referencias
[1]. Miller AD, et al. Delivery of RNAi therapeutics: work in progress. Expert review of medical devices. 2013 Nov;10(6):781-811. [Content Brief]
[4]. Hattori Y, et al. Effect of cationic lipid in cationic liposomes on siRNA delivery into the lung by intravenous injection of cationic lipoplex. Journal of drug targeting. 2019 Feb;27(2):217-227. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
AtuFECT01 Related Classifications
HY-112765 Related Classifications
Powered by Bioz